Cargando…
Impaired subendocardial perfusion in patients with metabolic syndrome
BACKGROUND: Metabolic Syndrome (MS) is associated to vascular damage, increased arterial stiffness, and impaired myocardial perfusion. Subendocardial viability ratio (SEVR) is a noninvasive estimation of myocardial workload, oxygen supply, and perfusion. The aim of the study was to describe the rela...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591647/ https://www.ncbi.nlm.nih.gov/pubmed/34772282 http://dx.doi.org/10.1177/14791641211047135 |
_version_ | 1784599295737987072 |
---|---|
author | Fantin, Francesco Giani, Anna Gasparini, Ludovico Rossi, Andrea P Zoico, Elena Mazzali, Gloria Zamboni, Mauro |
author_facet | Fantin, Francesco Giani, Anna Gasparini, Ludovico Rossi, Andrea P Zoico, Elena Mazzali, Gloria Zamboni, Mauro |
author_sort | Fantin, Francesco |
collection | PubMed |
description | BACKGROUND: Metabolic Syndrome (MS) is associated to vascular damage, increased arterial stiffness, and impaired myocardial perfusion. Subendocardial viability ratio (SEVR) is a noninvasive estimation of myocardial workload, oxygen supply, and perfusion. The aim of the study was to describe the relation between arterial stiffness, SEVR, and cardio-metabolic risk factors. METHODS: A cohort of 55 patients, aged 59.9 ± 10.8 years, was studied; 28 subjects (50.9%) had metabolic syndrome. All patients underwent a clinical evaluation and blood venous sampling, to assess glico-lipid profile. Applanation tonometry was performed, to obtain pulse wave analysis and SEVR values. RESULTS: In the overall study population, SEVR showed negative associations with mean (r = −0.301; p = 0.026) and systolic (borderline relation, r = −0.257; p = 0.058) arterial pressure. Metabolic syndrome patients presented lower level of SEVR (p = 0.012), even after adjusting for age, sex, and mean arterial pressure (p = 0.040). Subdividing the study population by the number of metabolic syndrome components, SEVR significantly decreased as the number of Metabolic Syndrome components increased (p for trend 0.005). In a logistic backward regression analysis, both metabolic syndrome and mean arterial pressure resulted significant predictors of SEVR, accounting for 18% of variance. CONCLUSION: The reduced SEVR in metabolic syndrome patients could be an important pathophysiological determinant of the increased cardiovascular risk. |
format | Online Article Text |
id | pubmed-8591647 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-85916472021-11-16 Impaired subendocardial perfusion in patients with metabolic syndrome Fantin, Francesco Giani, Anna Gasparini, Ludovico Rossi, Andrea P Zoico, Elena Mazzali, Gloria Zamboni, Mauro Diab Vasc Dis Res Original Article BACKGROUND: Metabolic Syndrome (MS) is associated to vascular damage, increased arterial stiffness, and impaired myocardial perfusion. Subendocardial viability ratio (SEVR) is a noninvasive estimation of myocardial workload, oxygen supply, and perfusion. The aim of the study was to describe the relation between arterial stiffness, SEVR, and cardio-metabolic risk factors. METHODS: A cohort of 55 patients, aged 59.9 ± 10.8 years, was studied; 28 subjects (50.9%) had metabolic syndrome. All patients underwent a clinical evaluation and blood venous sampling, to assess glico-lipid profile. Applanation tonometry was performed, to obtain pulse wave analysis and SEVR values. RESULTS: In the overall study population, SEVR showed negative associations with mean (r = −0.301; p = 0.026) and systolic (borderline relation, r = −0.257; p = 0.058) arterial pressure. Metabolic syndrome patients presented lower level of SEVR (p = 0.012), even after adjusting for age, sex, and mean arterial pressure (p = 0.040). Subdividing the study population by the number of metabolic syndrome components, SEVR significantly decreased as the number of Metabolic Syndrome components increased (p for trend 0.005). In a logistic backward regression analysis, both metabolic syndrome and mean arterial pressure resulted significant predictors of SEVR, accounting for 18% of variance. CONCLUSION: The reduced SEVR in metabolic syndrome patients could be an important pathophysiological determinant of the increased cardiovascular risk. SAGE Publications 2021-11-12 /pmc/articles/PMC8591647/ /pubmed/34772282 http://dx.doi.org/10.1177/14791641211047135 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Article Fantin, Francesco Giani, Anna Gasparini, Ludovico Rossi, Andrea P Zoico, Elena Mazzali, Gloria Zamboni, Mauro Impaired subendocardial perfusion in patients with metabolic syndrome |
title | Impaired subendocardial perfusion in patients with metabolic syndrome |
title_full | Impaired subendocardial perfusion in patients with metabolic syndrome |
title_fullStr | Impaired subendocardial perfusion in patients with metabolic syndrome |
title_full_unstemmed | Impaired subendocardial perfusion in patients with metabolic syndrome |
title_short | Impaired subendocardial perfusion in patients with metabolic syndrome |
title_sort | impaired subendocardial perfusion in patients with metabolic syndrome |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591647/ https://www.ncbi.nlm.nih.gov/pubmed/34772282 http://dx.doi.org/10.1177/14791641211047135 |
work_keys_str_mv | AT fantinfrancesco impairedsubendocardialperfusioninpatientswithmetabolicsyndrome AT gianianna impairedsubendocardialperfusioninpatientswithmetabolicsyndrome AT gaspariniludovico impairedsubendocardialperfusioninpatientswithmetabolicsyndrome AT rossiandreap impairedsubendocardialperfusioninpatientswithmetabolicsyndrome AT zoicoelena impairedsubendocardialperfusioninpatientswithmetabolicsyndrome AT mazzaligloria impairedsubendocardialperfusioninpatientswithmetabolicsyndrome AT zambonimauro impairedsubendocardialperfusioninpatientswithmetabolicsyndrome |